Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Obiltoxaximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Obiltoxaximab. |
| Estrone | Estrone may increase the thrombogenic activities of Obiltoxaximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Obiltoxaximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Obiltoxaximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Obiltoxaximab. |
| Estriol | Estriol may increase the thrombogenic activities of Obiltoxaximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Obiltoxaximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Obiltoxaximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Obiltoxaximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Obiltoxaximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Obiltoxaximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Obiltoxaximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Obiltoxaximab. |
| Equol | Equol may increase the thrombogenic activities of Obiltoxaximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Obiltoxaximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Obiltoxaximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Obiltoxaximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Obiltoxaximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Obiltoxaximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Obiltoxaximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Obiltoxaximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Obiltoxaximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Obiltoxaximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Obiltoxaximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Obiltoxaximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obiltoxaximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Obiltoxaximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obiltoxaximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Obiltoxaximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Obiltoxaximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Obiltoxaximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Obiltoxaximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Obiltoxaximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obiltoxaximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Obiltoxaximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obiltoxaximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Obiltoxaximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Obiltoxaximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Obiltoxaximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Obiltoxaximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obiltoxaximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Obiltoxaximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Obiltoxaximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Obiltoxaximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Obiltoxaximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Obiltoxaximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Obiltoxaximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Obiltoxaximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Obiltoxaximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Obiltoxaximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Obiltoxaximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Obiltoxaximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Obiltoxaximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Obiltoxaximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Obiltoxaximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Obiltoxaximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Obiltoxaximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Obiltoxaximab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Canakinumab. |